INTRODUCTION
Despite recent developments in cancer immunotherapies, clinical benefit occurs in a minority of patients. This has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2) , and the recently U.S. Food and Drug Administration-approved agents Provenge for prostate cancer (3) and anti-CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4) . Recent work has suggested that one explanation for tumor resistance to immunotherapies might be due to immunosuppressive events that act at the level of the tumor microenvironment (5) . Key mechanisms that have been observed in clinical samples and validated as functionally important in mouse models include extrinsic suppression of CD8 + effector cells by CD4 + CD25 + FoxP3 + regulatory T cells (T regs ) (6) , metabolic deregulation via tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO) (7) , and engagement of the inhibitory receptor PD-1 by the ligand PD-L1/B7-H1 (8, 9) . Clinical strategies to counter these immunosuppressive pathways are currently being evaluated, already with encouraging early-phase clinical trial results (10) (11) (12) . However, the mechanisms by which these immunosuppressive pathways become recruited and functionally operational within the tumor microenvironment are not clear, and which subsets of patients might express these pathways and theoretically benefit from targeting them are incompletely understood.
We and others recently have analyzed a series of melanoma metastases by gene expression profiling and confirmatory assays, and found that some samples contain abundant CD8 + T cell infiltrates and some do not (13) (14) (15) (16) . Spontaneously primed CD8 + T cells specific for defined melanoma antigens have also been identified in the peripheral blood in a subset of patients (2, 17, 18) . The T cell-inflamed subset also expresses chemokines for T cell recruitment (13) and a type I interferon (IFN) transcriptional profile that appears to participate in innate immune sensing (19, 20) . Clinical responders to melanoma vaccines and to ipilimumab appear to be enriched in the T cellinflamed subset of tumors, suggesting that an ongoing dialogue between the tumor and the host immune response may be predictive of clinical benefit (14, 21) . However, even if one were to enrich for patients having the inflamed tumor phenotype, fewer than half of the patients would still be estimated to respond, suggesting that additional barriers might need to be overcome to maximize therapeutic efficacy. With this notion in mind, more detailed analysis of our gene expression profiling data was performed and revealed that the T cell-inflamed subset of melanomas included those tumors showing high expression of the inhibitory factor IDO. Further interrogation of those samples revealed high expression of PD-L1/B7-H1 and also abundant FoxP3 + T regs . Mechanistic studies in mice were performed to determine causal relationships, and our data indicate that up-regulated expression of IDO and PD-L1/B7-H1, as well as accumulation of T regs , in the melanoma tumor microenvironment depended on CD8 + T cells. IDO and PD-L1/B7-H1 up-regulation was dependent on IFN-g. T reg accumulation was not due to CD8 + T cells promoting conversion from FoxP3 − CD4 + cells, but rather was largely due to the production of CCR4-binding chemokines with an additional contribution of induced proliferation. Collectively, these results suggest that the presence of these immunosuppressive factors in melanoma metastases is immune-intrinsic and driven by CD8 + T cells. Regarding clinical application of checkpoint blockade, these data imply that T reg depletion, PD-1/PD-L1 blockade, and IDO inhibitors may be beneficial preferentially in the subset of patients already showing a T cell-inflamed tumor microenvironment, and that alternative therapeutic strategies might be required for patients showing absence of spontaneous inflammation and adaptive immunity.
RESULTS
Melanoma metastases that contain activated T cells have highest expression of the immunosuppressive pathways IDO, PD-L1, and T regs Affymetrix gene expression profiling and confirmatory assays recently revealed that some melanoma metastases contain abundant CD8 + T cells, a broad chemokine signature, and a type I IFN transcriptional profile (13, 14, 19) . On the basis of parallel work suggesting dysfunction of CD8 + T cells when analyzed directly from the tumor microenvironment ex vivo (22) (23) (24) , those tumors were also interrogated for the presence of putative negative regulatory mechanisms that might inhibit effector T cell function. Reanalysis of the gene array data revealed that the inflamed melanoma subset also contained the tumors with elevated IDO expression (GSE12627). IDO is a tryptophanmetabolizing enzyme that has been shown to contribute to peripheral immunologic tolerance (25) . Examination of a second immunoregulatory metabolic enzyme, arginase I, revealed expression only in a subset of non-T cell-inflamed tumors, arguing that it may be less functionally relevant for inhibiting the function of T cells present in the tumor microenvironment. Because of the presence of IDO transcripts, these tumors were also interrogated for expression of other molecules indicative of distinct mechanisms of immune suppression. Expression of PD-L1/B7-H1, an inhibitory ligand that engages the negative regulatory receptor PD-1 on activated T cells (8) , and FoxP3, a marker for T regs (26) , was examined. Indeed, quantitative reverse transcription polymerase chain reaction (qRT-PCR) showed higher expression of IDO, PD-L1, and FoxP3 in the tumors that contained CD8 + T cells. A strong positive correlation between expression of IDO, PD-L1, and FoxP3 transcripts (correlation coefficient = 0.999 for each paired relationship; Pearson correlation), suggesting a coordinated up-regulation of at least three immunosuppressive mechanisms in the microenvironment of inflamed tumors (Fig. 1A) .
A subset of melanoma metastases from which we had sufficient material for immunohistochemical (IHC) analysis was interrogated in more detail for expression of these markers at the protein level. Tumors with the inflamed gene expression profile showed the presence of CD8 + T cells by IHC (Fig. 1B) . These tumors also showed the presence of lymphocytes with nuclear FoxP3 staining, consistent with the presence of T regs . Double staining revealed that FoxP3 was expressed by CD4 + T cells and not by CD8 + cells ( fig. S1 ). In addition, PD-L1 protein was detected at high levels, as was expression of IDO (Fig. 1B) . PD-L1 and IDO appeared to be expressed at least by tumor cells based on morphology but also could be expressed by some stromal cells. In contrast, melanoma metastases that lacked a CD8 + T cell infiltrate showed minimal expression of FoxP3, PD-L1, or IDO (Fig. 1B) . Statistical analysis over a panel of samples revealed a positive correlation (Pearson correlation, P < 0.0001) between the number of CD8 + T cells and the number of FoxP3 + T regs (Fig. 1C) , as well as with the expression of PD-L1 and IDO (Fig. 1, D and E) . Together, these data indicate that the abundance of these three immune inhibitory factors is correlated with the degree of infiltration of melanoma metastases with CD8 + T cells.
Up-regulation of IDO and PD-L1 in the tumor microenvironment in vivo is dependent on CD8 + T cells and IFN-g On the basis of the above correlative data, we turned to murine in vivo models to consider mechanisms by which CD8 + T cells might promote induction of PD-L1 and IDO, as well as accumulation of T regs , in the tumor microenvironment in vivo. The fact that IDO and PD-L1 can be induced by proinflammatory cytokines such as IFN-g in vitro (8, 27) suggested that cytokines produced by activated CD8 + T cells in the tumor microenvironment could explain the elevated expression of these factors preferentially in inflamed tumors in vivo. B16 melanoma expressed low levels of IDO mRNA and of PD-L1/B7-H1 protein in vitro ( fig. S2, A and B) . However, implantation of B16.SIY melanoma cells subcutaneously into immunocompetent C57BL/6 mice followed by reanalysis after 7 days ex vivo revealed marked up-regulation of both IDO and PD-L1/B7-H1 mRNA and also PD-L1/B7-H1 protein expression (Fig. 2, A and B, and fig. S2 , A and B, for B16 in vivo). When B16. SIY melanoma cells were implanted in mice depleted of CD8 + T cells, or into IFN-g-deficient mice, this up-regulation failed to occur (Fig. 2,  A and B) . Increased expression of class I and II major histocompatibility complex (MHC) molecules on the tumor cells also required CD8 + T cells ( fig. S2, C and D) . Therefore, up-regulated expression of both IDO and PD-L1/B7-H1 in the melanoma tumor microenvironment in vivo depends on CD8 + T cells and IFN-g. This model also was used to explore a role for CD8 + T cells in T reg accumulation within the tumor microenvironment. T regs were confirmed to accumulate in B16.SIY melanoma tumors after 7 days of implantation in vivo, both by FoxP3 RT-PCR analysis and using flow cytometry to assess the presence of CD4
+ cells among dissociated tumor cells ex vivo (Fig. 2, C and D) . This T reg accumulation was markedly reduced in mice depleted of CD8 + T cells but not significantly altered in IFN-g −/− mice (Fig. 2, C and D) . These results confirm that CD8 + T cells are required for maximal accumulation of T regs in the melanoma tumor microenvironment in vivo, but largely via a mechanism independent of IFN-g. T reg accumulation in the tumor microenvironment is mediated via a combination of CD8 + T cell-dependent chemokine-mediated recruitment and induced proliferation Two other potential mechanisms by which CD8 + T cells could support accumulation of T regs in the tumor microenvironment are induced proliferation of T regs and production of chemokines that promote T reg recruitment. To determine whether the proliferative rate of T regs in vivo was influenced by CD8 + T cells, C57BL/6 mice were depleted of CD8 + T cells or treated with an isotype control antibody, and B16 melanoma was implanted subcutaneously. On day 7, a single dose of 5-bromo-2′-deoxyuridine (BrdU) was injected intraperitoneally, and 1 day later, the tumor and lymph nodes were harvested for flow cytometric analysis of the T reg population. As shown in Fig. 4 , about 26% of T regs in the draining lymph nodes were BrdU-positive in tumor-bearing mice, and this fraction was not altered with CD8 + T cell depletion. In contrast, in the tumor microenvironment, the total number of T regs was reduced when CD8 + T cells were eliminated, consistent with what we had observed previously. In addition, the proportion of remaining T regs incorporating BrdU was modestly reduced, from about 27 to 10% (Fig. 4) . Although the absolute number of T regs in tumors from CD8-depleted mice was small (mean of 200 T regs per tumor) and 
FoxP3
+ cells. Shown is the mean ± SEM and tested for significance using one-way analysis of variance (ANOVA) (Kruskal-Wallis) test (WT = 5; IFN-g = 6; CD8-depleted = 5) with P = 0.0016 for IDO expression, P = 0.01 for PD-L1 expression, and P = 0.0003 for FoxP3 expression (qRT-PCR and FACS). The results shown are representative of two independent experiments, which were combined for statistical purposes. KO, knockout; n.s., not significant. therefore subject to the caveat of difficulty quantifying small frequencies, this reduction was statistically significant (P < 0.0001). Therefore, CD8
+ T cells may support T reg accumulation in the tumor microenvironment, at least in part, through induced proliferation of T regs in situ.
Because the reduction in the proliferating fraction of T regs was modest compared to the reduction in total T regs in the tumor microenvironment when CD8 + T cells were depleted, it seemed likely that T reg recruitment also might be critically regulated. Because previous work suggested that chemokines could contribute to T reg accumulation in tissues (28), we evaluated whether CD8 + effector T cells might produce any chemokines capable of T reg recruitment and whether chemokine-mediating trafficking participated in vivo. Rag2 −/− mice were implanted with B16 melanoma tumors and reconstituted intravenously with 1 × 10 6 splenic CD4 + CD25 + T cells either with or without previous administration of CD8 + T cells. Two days later, the tumor was harvested, and T reg infiltration was quantitated by flow cytometry. As shown in Fig. 5A , significant accumulation of T regs in the tumor was only observed when CD8 + T cells were present (P = 0.0087, MannWhitney U test; n = 6). Flow cytometric analysis confirmed that most of the T regs expressed the chemokine receptor CCR4 (fig. S4A ). To determine whether chemokine receptor signaling in T regs was necessary for their accumulation in the tumor site, the T regs were pretreated with pertussis toxin before in vivo transfer to block chemokine receptor signaling. This treatment completely prevented T reg accumulation in the tumor microenvironment. To assess whether CCR4 was specifically involved, T regs were pretreated with the CCR4 antagonist C021. This treatment also prevented T reg accumulation in the tumor (Fig.  5A ). In contrast, neither pertussis toxin nor C021 affected the number of T regs detected in lymphoid organs (Fig. 5B) , arguing that their distribution, but not survival, was affected. The defined chemokine . Using a two-sided MannWhitney U test to compare the two proliferated fractions, we confirmed a significantly reduced proliferation rate within the tumor-infiltrating T regs under CD8-depleting conditions. *P = 0.002; **P = 0.0094.
ligands for CCR4 are CCL17 and CCL22. In vitro-primed CD8 + T cells were analyzed for chemokine production after restimulation in vitro, and significant production of CCL22 mRNA was detected (Fig. 5C ), which was confirmed by CCL22 enzyme-linked immunosorbent assay (ELISA) (fig. S4C ). Purified CD8 + T cells harvested from the B16 tumor microenvironment were also analyzed and were similarly found to produce CCL22 (Fig. 5C) but not CCL17 (fig. S4B ). Together, these data indicate that the major mechanism by which CD8 + T cells support T reg accumulation in the tumor microenvironment is through the production of CCL22 and recruitment of T regs via CCR4.
Human CD8
+ T cells support the recruitment of human T regs in a xenograft system It was of interest to confirm whether human CD8 + T cells also could support recruitment of human T regs into the melanoma tumor microenvironment. Purified CD8 + T cells from normal human donors were stimulated with anti-CD3/anti-CD28 mAb-coated beads for 10 days to generate primed effector cells (29) . Supernatants from purified activated human CD8 + T cells were therefore analyzed for chemokine production, and as with mouse cells, CCL22 was detected in T cell supernatants (Fig. 6A) hi cells. Activated CD8 + T cell supernatants were capable of promoting strong chemotaxis of T regs in vitro, to the same extent as recombinant CCL22 (Fig. 6B) . In addition, a neutralizing anti-CCL22 mAb blocked most of the migration observed with the CD8 + T cell supernatants, down to the level of background migration detected upon treatment with pertussis toxin as an inhibitor of chemokine receptor function (Fig. 6B) .
To determine whether the presence of human CD8 + effector T cells could support recruitment of T regs into the tumor microenvironment in vivo, a human melanoma xenograft model was used. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were inoculated subcutaneously with the human melanoma cell line M537, which we previously observed expresses several chemokines capable of recruiting CD8 + effector T cells (including CCL3, CCL4, and CCL5) (13) . Tumors were allowed to grow for about 4 weeks, at which time the tumor diameter was 0.5 to 1 cm. Normal donor T regs were isolated by flow cytometric sorting, and CD8 + effector cells were generated in vitro as described above. These cell populations were injected intravenously alone or in combination, and tumors were harvested 24 hours later for analysis of infiltrating T cell populations by flow 
cells in vivo. (A and B) B16 cells were engrafted into Rag2
−/− (subcutaneously) followed, 24 hours later, by injection of 3 × 10 6 CD8 + T cells (intravenously) (if indicated), and on day 10 after tumor inoculation, 1 × 10 6 T regs (CD4 + CD25 + ) were given (intravenously). PTX T regs were treated with pertussis toxin for 1.5 hours in vitro before injection, and C021 T regs were treated with the CCR4 antagonist C021 for 2 hours before injection. Forty-eight hours after T reg injection, tumor and spleen were analyzed for the number of infiltrating T regs (CD3 + , CD4 + , FoxP3 + ). T regs could only be detected in the tumor site if nontreated and given in combination with pre-engrafted CD8 + T cells (A), whereas chemokine receptor inhibitory treatment did not alter homing to the spleen (B). Shown are means ± SEM of n = 6 out of two independent experiments; significance was tested using two-sided Mann-Whitney U test (**P = 0.0024; ****P < 0.0001). (C) Naïve (CD62L + ) CD8 T cells were cultured for 6 hours or 7 days ± 6 hours or assayed ex vivo. After activation, mRNA expression levels of CCL22 were assessed by qRT-PCR, normalized to 18S RNA, and were relative to the ex vivo expression level of CCL22 (*) (left panel). Tumorinfiltrating CD8 T cells were sorted out of B16 tumors 12 days after engraftment and analyzed either ex vivo or after activation for 6 hours (right panel). Shown are means ± SEM of n = 3, with numbers indicating the fold change compared to ex vivo naïve or tumor-infiltrating CD8 + T cells.
cytometry. When T regs were transferred alone, a minimal number were detected in the tumor microenvironment. However, this number was significantly increased when CD8 + effector cells were also delivered (Fig.  6C) . Thus, human CD8 + effector T cells can promote increased migration of T regs into the melanoma tumor microenvironment in vivo.
DISCUSSION
A major subset of human melanomas lacks evidence for innate immune activation, chemokine production, and T cell markers. Immune escape in that subset appears to be a consequence of immunologic ignorance and/or immune "exclusion" (13, 14, 30) . However, for the subset of tumors that does show a strong inflammatory response including accumulation of antigen-specific CD8 + T cells, the mechanism of immune escape has been less clear, and the goal of our current study was to elucidate this process using human melanoma metastases as a foundation combined with mouse mechanistic experiments. Our results indicate that CD8 + T cell-infiltrated tumors contain high presence of CD4
+ T regs , as well as expression of IDO and PD-L1, arguing that immunosuppressive mechanisms dominate in these tumors and prevent optimal T cell function. In addition, and contrary to initial preconceptions, our data argue that the recruited involvement of these immunosuppressive pathways is intrinsic to the immune system and likely represents a set of physiologic negative feedback loops.
Our murine mechanistic experiments demonstrated that the induction of IDO and PD-L1 in the melanoma tumor microenvironment is mediated by CD8 + T cells and IFN-g. In some tumor cell lines, PD-L1 expression appears to be up-regulated intrinsically via PTEN silencing and Akt activation (31) . There may be a functional distinction between tumors having intrinsic PD-L1 expression and those in which PD-L1 is induced via adaptive immune cells. It has been speculated that clinical response to antibodies targeting the PD-L1/PD-1 interaction may end up being restricted to cases in which PD-L1 expression is associated with a CD8 + T cell infiltrate and therefore is likely blunting host immunity (32) . It is also conceivable that in some cases, natural killer cells could contribute to up-regulation of these molecules through IFN-g, although our mechanistic experiments demonstrated that CD8 + T cells were required.
The CD8 + T cell-dependent accumulation of T regs largely appeared to be driven by CCR4-binding chemokines, with a component of induced T reg proliferation contributing. In vitro, the only chemokine produced by primed human CD8 + effector T cells capable of inducing migration of T regs was CCL22, which also was the only defined CCR4 ligand found to be produced by tumor-infiltrating lymphocytes (TILs) in vivo. These results are consistent with reports indicating a role for this chemokine in transplantation tolerance via T reg recruitment (33) . Although direct CCL22 production by tumor cells in other cancer types also has been suggested (34), we did not detect CCL22 mRNA expression in a series of melanoma cell lines, arguing that in the melanoma context, it is likely derived from infiltrating nontumor stromal cells (13) . Although our current results indicated that activated CD8 + T cells themselves are one source of CCL22, they do not exclude a contribution of CCL22 from other stromal cell components such as macrophages, although our mechanistic experiments indicated that CD8 + T cells were required for T reg accumulation in the tumor. In addition to CCL22, our results do not exclude a role for other chemokines 
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CD8 supernat. hi cells were added to the top wells, and 2 hours later, the cells that migrated to the bottom well were counted. Data represent means ± SEM and are representative of three independent experiments done in duplicate. PTX, pertussis toxin-treated T regs . (C) The indicated cell subsets were injected into mice bearing human melanoma xenografts by tail vein injection. Forty-eight hours later, tumors were collected, made into single-cell suspensions, and stained for human CD8, CD4, and FoxP3. Representative FACS plots are shown for two independent experiments done with five mice in each group. P < 0.01, T reg cell injection followed by CD8 + T cell injections versus T regs injected alone. (35) . If IDO, PD-L1, and T regs represent immune-intrinsic negative feedback loops, then the question arises as to why tumors are not rejected if initial accumulation of CD8 + effector cells occurs unencumbered by these inhibitory pathways. One potential immune inhibitory mechanism that might be more directly attributable to the tumor itself is T cell anergy (36) . Most solid tumor cells lack expression of the costimulatory molecules B7-1 and B7-2, which would favor anergy induction. Indeed, our gene expression profiling analyses revealed background levels of B7-1 and B7-2 transcripts in most of the tumors, arguing that collective expression of these molecules by tumors and their stromal cells also is likely low. Previous work has shown that antigen-presenting cells in the tumor microenvironment can be tolerogenic (37) , and that some cytokines abundant in the tumor, such as IL-10, can inhibit dendritic cell activation and result in T cell anergy (38) . Mechanistic studies have suggested that prevention or reversal of a T cell anergic state can promote tumor rejection in vivo (39) (40) (41) . One could therefore envision that a costimulation-poor tumor microenvironment might lead to classical anergy, which would lead to defective IL-2 production and proliferation and diminished activity of other effector functions. It is noteworthy that in vitro models have demonstrated that anergic T cells produce reduced but still detectable levels of IFN-g (36) , which would be available to induce IDO and PD-L1 expression. Expression of the latter would then cooperate to inhibit the activation of additional T cells trafficking into the tumor microenvironment. Whether anergic T cells continue to produce chemokines such as CCL22 has not been reported, but it is of interest that tumor-infiltrating CD8 + T cells (many of which are dysfunctional) did produce CCL22 in our current study.
R E S E A R C H A R T I C L E
Our study is limited in that we focused our attention on three major immune inhibitory mechanisms in this study (PD-L1, IDO, and T regs ) because they are associated with the presence of a CD8 + T cell infiltrate and therefore are candidates for inhibiting T cell function at the tumor site. Several other candidate inhibitory mechanisms have been described, including secretion of the cytokines IL-10 or TGF-b (transforming growth factor-b), or extrinsic suppression by myeloidderived suppressor cells. Although we have not found these to be associated with a T cell infiltrate in melanoma metastases, or to be linked to clinical outcome to vaccination, these factors could nonetheless contribute to immune evasion.
Several strategies are being pursued clinically to counter the inhibitory effect of these negative regulatory mechanisms as a strategy for cancer immunotherapy. These include antibodies against PD-1 or PD-L1 (11, 42, 43) , small-molecule inhibitors of IDO (44), and reagents targeting CD25 to deplete T regs (12) . Some of these approaches have already demonstrated clinical activity in subsets of melanoma patients. Our current results suggest that the efficacy of these strategies might be restricted to those patients having a T cell-inflamed tumor microenvironment and the accompanying up-regulation of the targets of these agents. Early data analyzing PD-L1 expression in tumors as a predictive indicator support this notion (32) . Because multiple immune inhibitory pathways appear to be involved concurrently to facilitate immune escape, our data also imply that combination therapies may be advantageous to target two or more immunosuppressive simultaneously. Indeed, preclinical data support the notion that combinatorial manipulation of two immunoregulatory pathways can provide synergy for improved immune-mediated tumor control in vivo (6, 45, 46) .
MATERIALS AND METHODS

Study overview
Patient-derived samples were analyzed by IHC for immunoregulatory molecules. Data analysis was done in a blinded fashion, and counting was done three times. Mechanistic experiments were performed in mice and were carried out at least twice, in an independent way. Both experiments were expected to give similar results to generate conclusions. All experiments were designed to have at least three mice per group, with higher mouse numbers being used for experiments having a broader value distribution.
Patient samples
Melanoma metastases were pretreatment biopsies from patients participating in immunotherapy trials at the University of Chicago. All patients provided written informed consent that included tissue studies for biomarker analysis. For RNA analysis and gene expression profiling, samples were flash-frozen and stored at −80°C. When sufficient material was available, additional samples were formalin-fixed and embedded for IHC.
Reverse transcription-polymerase chain reaction Total RNA was deoxyribonuclease (DNase) I-treated, and complementary DNA (cDNA) was synthesized from 1 mg of total RNA with M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's directions. Reactions were run on an ABI Prism 7300 Sequence Detection System machine and analyzed. Prevalidated primers and probes specific for CD8 (Hs02621753_m1) and FoxP3 (Hs02622129_m1) were purchased from Applied Biosystems. The primer/probe sets for IDO and PD-L1 are as follows: IDO M34455 (forward: 5′-tggagaaagcccttcaagtgtt-3′, reverse: 5′-TCATACACCAGACCGTCTGAT-3′, probe: 6FAM-TCTGGCT-GGAAAGGCAACCCCC-TAMRA) and PD-L1 NM_014143 (forward: 5′-tctggcacatcctccaaatg-3′, reverse: 5′-CAGTGCTACACCAAGGCA-TAATAAG-3′, probe: 6FAM-aaggactcacttggtaattctgggagcca-TAMRA). For mouse experiments, RT-PCR was performed with commercial Roche probes for FoxP3 (together with primers forward: 5′-aaacacccagccactcca-3′ and reverse: 5′-cttccaagtctcgtctgaagg-3′), IDO (5′-gggcttcttcctcgtctctc-3′ and 5′-tggatacagtggggattgct-3′), PD-L1 (5′-ccatcctgttgttcctcattg-3′ and 5′-tccacatctagcattctcacttg-3′), and CCL22 (5′-tcttgctgtggcaattcaga-3′ and 5′-gcagagggtgacggatgtag-3′) (Roche Applied Science).
Immunohistochemistry
Melanoma biopsies were immunostained with mouse antibodies for CD8 (NeoMarkers) and/or FoxP3 (Abcam). After tris-buffered saline (TBS) washing, secondary goat anti-mouse immunoglobulin G (IgG) conjugated to a horseradish peroxidase (Envision+ System, DAKO) or to an alkaline phosphatase (Biocare Medical) was applied. Reactions were developed with 3,3′-diaminobenzidine (DAB) chromogen or Vulcan Red, respectively, and counterstained with hematoxylin. Appropriate negative controls for the immunostaining were prepared by omitting the primary antibody step and substituting it with nonimmune mouse serum.
The anti-PD-L1/B7-H1 murine IgG antibody was a gift from L. Chen. Tissue sections were deparaffinized and rehydrated through xylenes and serial dilutions of ethanol to deionized water. They were incubated in antigen retrieval buffer (pH 9, DAKO, S2367) and heated in a steamer at greater than 97°C for 20 min. Anti-B7-H1 antibody (1:1000) was applied on tissue sections for overnight incubation at 4°C temperature. After TBS wash (0.05 M tris base, 0.9% NaCl, pH 8.4), tissue sections were incubated with biotinylated anti-mouse IgG (1:100, BA-2001, Vector Laboratories) followed by Elite ABC kit for 30-min incubation at room temperature. The antigen-antibody binding was detected with the TSA Biotin System (NEL700A001KT, PerkinElmer) and DAB (DAKO, K3468).
The anti-IDO rabbit antiserum was a gift from R. Netwon (Incyte Pharmaceuticals). Tissue sections were treated as for the anti-PD-L1 antibody above. Anti-IDO antibody (1:1000) was applied on tissue sections for overnight incubation at 4°C. After TBS wash, tissue sections were incubated with biotinylated anti-rabbit IgG (1:200 dilution, BA-1000, Vector Laboratories) for 30-min incubation at room temperature. The antigen-antibody binding was detected by Alkaline Phosphatase Standard ABC kit (AK-5000, Vector Laboratories) and Vulcan Fast Red (FR850s, Biocare Medical) system. Tissue sections were briefly immersed in hematoxylin for counterstaining and were covered with cover glasses.
Antibodies and flow cytometry
If not indicated differently, all analyses using flow cytometry were performed with the FoxP3 staining kit (BD Biosciences) according to the manufacturer's instructions combined with the fixable live/death discrimination dye (eFlour 450, eBioscience). The following antibodies were used throughout the study: anti-CD3 AF700 (clone 17A2), anti-FoxP3 APC (allophycocyanin) (clone JFK-16a), anti-BrdU FITC (fluorescein isothiocyanate) (clone Bu20a), anti-PD-L1 PE (phycoerythrin) (clone MIH5) (eBioscience), anti-CD4 peridinin chlorophyll protein (PerCP)-Cy5.5 (clone RM4-5), anti-CD8 APC-Cy7 (clone 53-6.7) (BioLegend), and anti-CD25 PE (clone PC61) (BD Biosciences). Samples were acquired on the LSR2 blue (BD Biosciences) and analyzed with FlowJo software (TreeStar).
B16 melanoma in vivo tumor experiments B16 and GFP + B16.SIY melanoma cells were cultured as described (47) . GFP + B16.SIY cells (1 × 10 6 ) were inoculated subcutaneously in 6-weekold wild-type or IFN-g −/− C57BL/6 mice (Jackson Laboratories). Some mice were intraperitoneally injected with 100 mg of isotype control or CD8-depleting antibody twice a week (starting at day −1; BioXCell). The CD8 depletion was confirmed by FACS. At day 7, tumors and spleens (as control) were harvested and split in two to be either saved in RNAlater (Ambion Inc.) for RT-PCR analysis or used to prepare single-cell suspensions for immediate FACS analysis for CD4, CD8, PD-L1, and FoxP3 as described (6, 48) .
In vivo T reg conversion assay B16 cells were injected subcutaneously in 6-week-old Rag2 −/− (Jackson Laboratories) mice on day 0. The following day, GFP-expressing splenocytes from FoxP3-GFP reporter mice (49) were removed by sorting, and 3 × 10 6 GFP-depleted or total splenocytes were injected intravenously into tumor-bearing mice. On day 7 after tumor inoculation, tumor and tumor-draining lymph nodes were collected and processed into single-cell suspensions for subsequent analysis by flow cytometry. Cells were analyzed with live/dead discrimination and stained for CD3, CD4, CD8, CD25, and FoxP3. The experiment was confirmed with wild-type donor mice depleted for CD4 + CD25
+ cells using Miltenyi kits (according to the manufacturer's instructions).
In vivo T reg proliferation assay B16 cells (2 × 10 6 ) were injected subcutaneously in 6-week-old wildtype mice treated with CD8-depleting antibody or isotype control as described above. On day 7 after tumor inoculation, one dose of BrdU (0.8 mg per mouse) (BD Biosciences) was given intraperitoneally, and 24 hours later, the tumor and tumor-draining lymph nodes were collected and processed into single-cell suspensions for subsequent analysis by flow cytometry. Cells were analyzed with live/dead discrimination and stained for CD3, CD4, CD8, CD25, FoxP3, and BrdU (according to the manufacturer's instructions for BrdU staining kit, eBioscience).
In vivo T reg recruitment assay B16 cells (2 × 10 6 ) were injected subcutaneously into 6-week-old Rag2 −/− (Jackson Laboratories) mice on day 0. The following day, 3 × 10 6 MACS-purified CD8 + T cells (Miltenyi kit according to the manufacturer's instructions) from wild-type mice were injected intravenously if indicated. On day 10 after tumor inoculation, 1 × 10 6 CD4 + CD25 + MACS-enriched T regs were given intravenously. If indicated, T regs were pretreated in vitro with pertussis toxin (20 ng/ml for 1.5 hours) (SigmaAldrich) or C021 (60 nM for 2 hours) (Millipore), whereas untreated control T regs were cultured for the same time in medium. Forty-eight hours later, the tumor and tumor-draining lymph nodes were collected and processed into single-cell suspensions for subsequent analysis by flow cytometry. Cells were analyzed with live/dead discrimination and stained for CD3, CD4, CD8, CD25, and FoxP3.
In vitro and ex vivo T cell stimulation For naïve CD8 + T cells, spleens from wild-type mice were harvested, and single-cell suspension was prepared. Cells were negatively enriched for CD8 followed by positive enrichment for CD62L (both MACS Miltenyi kits, according to the manufacturer's instructions). Enriched cells were either used directly for RNA isolation and reverse transcriptase (Applied Biosystems) (ex vivo) or stimulated for the indicated time with anti-CD3-coated (5 mg/ml, clone 145-2C11, BioLegend) and anti-CD28-coated (3 mg/ml, clone EL4, BD Biosciences) plates. TILs were sorted with the FACSAria (BD Biosciences) by staining for CD3 and CD8. Isolated cells were stimulated on antibody-coated plates as described above for isolation of RNA and RT-PCR analysis.
Enzyme-linked immunosorbent assay
Human and mouse CCL22 was measured in triplicate from culture supernatants with commercially available kits from R&D Systems and analyzed with SoftMax analysis software (Molecular Devices).
Human T reg cell sorting and migration assay CD4 + lymphocytes were positively selected from normal donor peripheral blood mononuclear cells with the MACS CD4 + kit. Selected CD4 + cells were labeled with anti-CD4 and anti-CD25 fluorescenceconjugated antibodies. Natural T regs were then sorted by gating on bright CD25 expression. Sorted T regs were loaded onto the top chamber of Transwells (5-mm pore size, Costar) for migration analysis. A total of 500-ml recombinant chemokine (100 ng/ml), culture supernatants, or control media were plated in the bottom wells. The anti-CCL22-blocking antibody was purchased from R&D Systems. Migration was allowed to proceed for 1.5 to 2 hours, and the cells present in the bottom well were counted. Cultures were analyzed in triplicate, and mean ± SE was determined.
NOD/SCID tumor establishment T cell injections
Six-week-old NOD/SCID mice (five mice per group) were inoculated subcutaneously with the human melanoma cell line M537 (3 × 10 . After tumors were allowed to grow for about 4 weeks, activated purified CD8 + effector cells (3 × 10 6 per mouse) were injected into one group of mice by tail vein injection. The next day, sorted human T regs were injected into the indicated groups of mice intravenously. After an additional 48 hours, mice were sacrificed, and tumors were removed and minced into single-cell suspensions. Flow cytometric analysis was performed with antibodies specific for human CD8, CD4, and FoxP3 and then analyzed as above.
Statistical analysis
All statistical analyses were done with GraphPad Prism software (GraphPad). For all statistical analysis, we assumed non-Gaussian distribution due to sample size, and if not indicated otherwise, data are shown as means ± SEM. 
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